About ADVENTUS PARTNERS

Adventus was formed with the intent to provide small to mid – size life-science companies with well thought through, actionable strategic and operational advice.

Ana Radeljevic, Founder & CEO

Ana is a life science executive with extensive experience in strategic and business planning, finance, business development and operations. She held roles of increasing responsibility at Sanofi and Genzyme Corp. and most recently was VP of FP&A at PerkinElmer. While at Genzyme, Ana worked in corporate finance and supported BD and special projects for the office of CFO, such as divestiture of Genetic Testing, Diagnostics and Pharmaceuticals businesses, issuance of $1.0 billion in corporate debt and acquisition negotiations and Genzyme sale to Sanofi. At Sanofi, she led global forecasting for Renal and Biosurgery businesses and headed business planning and BD for Biosurgery working on acquisition of Pluromed, leading strategic efforts to maximize global commercial value of the portfolio and led divestiture of Cell Therapy and Regenerative Medicines business to Vericel. Ana started her career with Deloitte in audit and subsequently valuation practice. Ana received her MBA from Syracuse University and holds CPA and CFA designations.

Howard Goldsweig

Howard Goldsweig, Senior Consultant

Howard Goldsweig, MD is our Boston based Senior Consultant. He joined Adventus Partners in December of 2017. Dr. Goldsweig has extensive experience in research, drug development and medical affairs in the biotech industry, focused on the field of oncology. Previously, Dr. Goldsweig served as an Executive Medical Director at Amgen, and prior to that at Biovexis, company acquired by Amgen. Previously, he held roles of increasing responsibility in clinical drug development at Hoffmann La Roche, Bozell Healthcare, Qualus Medical Affairs and Averion. Prior to his executive positions in biotech and oncology companies, Dr. Goldsweig was a faculty member at College of Physicians and Surgeons of Columbia University. Also he practiced as a medical oncologist at Columbia-Presbyterian Hospital and St. Lukes-Roosevelt Medical Center. Dr. Goldsweig received an A.B. in zoology from Franklin and Marshall College and an M.D. from the State University of New York, Downstate Medical Center College of Medicine. Dr. Goldsweig completed his residency in internal medicine at the affiliated hospitals of the McGill University Faculty of Medicine and his medical oncology fellowship at Northwestern University School of Medicine. Dr. Goldsweig is board-certified in both oncology and internal medicine.